HK Stock Market Move | ANTENGENE-B(06996) rose by over 7% recently after reaching an exclusive licensing agreement for ATG-106 with K2. The company's TCE platform continues to deliver returns in the BD phase.

ANTENGENE-B (06996) surged over 7%, rising 7.39% to HK$4.36 as of press time, with a turnover of HK$76.179 million. In terms of news, recently, ANTENGENE-B announced that Antengene Biologics Limited (licensor, a wholly-owned subsidiary of the company) and a company newly established by K2 Therapeutics (K2) (licensee) have entered into an exclusive and potentially renewable license agreement for ATG-106 (an investigational CDH6CD3 bispecific T cell engager (TCE) targeting solid tumors). Soochow believes that the competitive advantage of the new generation TCE lies in balancing effectiveness, safety, tolerability, and coverage of low-expressing/difficult-to-treat targets, with global capabilities in this area still being scarce. Soochow pointed out that ANTENGENE-B, with its differentiated design of "spacer blockade + proprietary CD3 sequence," effectively clears pathogenic cells while significantly reducing the risk of CRS, has entered the top tier of global second-generation TCEs, and can flexibly expand across oncology and autoimmunity fields. By 2026, the company will have licensed ATG-201 (CD19CD3) to UCB (US$60 million upfront payment + US$20 million near-term milestone + up to US$1.1 billion milestone + tiered royalty fees), as well as licensing ATG-106 and others to K2 Therapeutics (potential maximum transaction consideration of US$1.921 billion), entering the phase of continuous realization of BD.